CD133 expression is known to be associated with activation of c-Src and required for maintenance of CSC phenotype through EMT modulation in head and neck cancer [47] CD133 rich subpopulations of orospheres with self-renewal capacity are exclusively tumorigenic [45, 48]. The gene discussed is SRC; the disease is head and neck cancer.